Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly Gets Expanded FDA EUA for Covid-19 Treatment for Some High-Risk Individuals

09/16/2021 | 05:02pm EDT

By Kimberly Chin

Eli Lilly & Co. said the U.S. Food and Drug Administration expanded the company's emergency use authorization for its combination Covid-19 treatment to include some individuals who may have a high risk of infection after being exposed to someone with the disease.

The drugs bamlanivimab and etesevimab, which are administered together, could be used to treat children who are 12 years of age or older who haven't been fully vaccinated or people who may not develop an adequate immune response after being fully vaccinated, the company said.

With the expanded authorization, the combination treatment could be used as a preventive treatment in an institutional setting, such as in a nursing home or prison, for certain individuals who may be exposed to someone with Covid-19 or who have a high risk of exposure, the company said.

"We're pleased that this expansion will help us provide antibody therapies as post-exposure prophylaxis to help prevent the spread of Covid-19 to some of the most at-risk individuals in the U.S.," Eli Lilly's Chief Science and Medical Officer Daniel Skovronsky said in prepared remarks.

Post-exposure prophylaxis refers to treatments that can be taken to prevent a virus after a potential exposure.

Write to Kimberly Chin at kimberly.chin@wsj.com

(END) Dow Jones Newswires

09-16-21 1701ET

All news about ELI LILLY AND COMPANY
10:01aEli Lilly Reports Higher Third-Quarter Results, Raises 2021 Forecast to Reflect Increas..
MT
09:56aGLOBAL MARKETS LIVE : Michelin, Facebook, UBS, Tesla, Volvo...
09:37aEli Lilly Intends to Complete US Marketing Application Submission for Alzheimer's Drug ..
MT
09:30aEli Lilly Alzheimer's Programs Head in Different Directions
DJ
09:17aHealth Care Stocks Edge Higher Premarket Tuesday
MT
09:11aEli Lilly, Pfizer Halt Program for Osteoarthritis Pain Drug
MT
08:51aLilly kicks off application for Alzheimer's drug U.S. approval, ups outlook
RE
08:33aWALL STREET STOCK EXCHANGE : Are companies fooling themselves on inflation?
07:31aLilly Cuts Income Targets, Lifts Sales Forecast For FY21
MT
07:16aLilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthe..
PU
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 350 M - -
Net income 2021 6 489 M - -
Net Debt 2021 11 548 M - -
P/E ratio 2021 34,8x
Yield 2021 1,32%
Capitalization 225 B 225 B -
EV / Sales 2021 8,66x
EV / Sales 2022 8,40x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 248,44 $
Average target price 269,42 $
Spread / Average Target 8,45%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY47.15%222 158
JOHNSON & JOHNSON5.32%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.22%241 929
MERCK & CO., INC.-0.17%206 712